Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D5T7QW
|
|||
| Drug Name |
LX2761
|
|||
| Synonyms |
1610954-97-6; LX-2761; N-(1-((2-(Dimethylamino)ethyl)amino)-2-methyl-1-oxopropan-2-yl)-4-(4-(2-methyl-5-((2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(methylthio)tetrahydro-2H-pyran-2-yl)benzyl)phenyl)-butanamide; CHEMBL4074614; SCHEMBL15741132; BDBM176714; EX-A2828; ACN-053194; AC-31562; HY-101122; CS-0020883; N-[2-(dimethylamino)ethyl]-2-methyl-2-[4-[4-[[2-methyl-5-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-methylsulfanyloxan-2-yl]phenyl]methyl]phenyl]butanoylamino]propanamide; US9688710, 136 N-(1-((2-(dimethylamino)ethyl)amino)-2-methyl-1-oxopropan-2-yl)-4-(4-(2-methyl-5-((2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(methylthio)tetrahydro-2H-pyran-2-yl)benzyl)phenyl)butanamide
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Type 2 diabetes [ICD-11: 5A11; ICD-10: E08-E13] | Phase 1 | [1] | |
| Company |
Lexicon Pharmaceuticals
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C32H47N3O6S
|
|||
| Canonical SMILES |
CC1=C(C=C(C=C1)C2C(C(C(C(O2)SC)O)O)O)CC3=CC=C(C=C3)CCCC(=O)NC(C)(C)C(=O)NCCN(C)C
|
|||
| InChI |
1S/C32H47N3O6S/c1-20-10-15-23(29-27(38)26(37)28(39)30(41-29)42-6)19-24(20)18-22-13-11-21(12-14-22)8-7-9-25(36)34-32(2,3)31(40)33-16-17-35(4)5/h10-15,19,26-30,37-39H,7-9,16-18H2,1-6H3,(H,33,40)(H,34,36)/t26-,27-,28+,29+,30-/m1/s1
|
|||
| InChIKey |
BNPZTRDIESRGTC-IXYVTWBDSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Sodium/glucose cotransporter 1 (SGLT1) | Target Info | Inhibitor | [1] |
| KEGG Pathway | Carbohydrate digestion and absorption | |||
| Bile secretion | ||||
| Mineral absorption | ||||
| Pathwhiz Pathway | Lactose Degradation | |||
| Trehalose Degradation | ||||
| Reactome | Hexose transport | |||
| Na+-dependent glucose transporters | ||||
| Inositol transporters | ||||
| WikiPathways | NRF2 pathway | |||
| Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds | ||||
| Metabolism of carbohydrates | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of Lexicon Pharmaceuticals. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.